BRAF (G464V)
Sign in to save this workspaceBRAF · Variant type: point · HGVS: p.G464V
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Ripretinib | 100.0% | 0.0% | 92.95 |
| 2 | Regorafenib | 98.1% | 1.9% | 95.99 |
| 3 | Encorafenib | 97.5% | 2.5% | 98.50 |
| 4 | Vemurafenib | 97.4% | 2.6% | 96.49 |
| 5 | Ponatinib | 97.3% | 2.7% | 78.23 |
| 6 | Dabrafenib | 96.8% | 3.2% | 94.74 |
| 7 | Nilotinib | 95.5% | 4.5% | 96.49 |
| 8 | Dasatinib | 93.7% | 6.3% | 87.97 |
| 9 | Sorafenib | 90.9% | 9.1% | 96.72 |
| 10 | Pacritinib | 78.5% | 21.6% | 88.64 |
| 11 | Erdafitinib | 77.3% | 22.6% | 95.71 |
| 12 | Apatinib | 52.2% | 47.8% | 97.73 |
| 13 | Pazopanib | 50.5% | 49.5% | 97.49 |
| 14 | Tivozanib | 49.3% | 50.7% | 92.42 |
| 15 | Gedatolisib | 48.5% | 51.5% | 99.75 |
| 16 | Rabusertib | 42.8% | 57.3% | 98.74 |
| 17 | Crizotinib | 41.4% | 58.6% | 91.39 |
| 18 | Dacomitinib | 40.0% | 60.0% | 97.99 |
| 19 | Umbralisib | 26.8% | 73.2% | 98.74 |
| 20 | Axitinib | 24.9% | 75.1% | 93.23 |
| 21 | Bosutinib | 22.8% | 77.2% | 87.22 |
| 22 | Imatinib | 19.2% | 80.8% | 99.00 |
| 23 | Gefitinib | 19.2% | 80.8% | 99.25 |
| 24 | Tenalisib | 19.2% | 80.8% | 97.98 |
| 25 | Osimertinib | 18.7% | 81.3% | 97.24 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Ripretinib | 100.0% | 100.0% | +0.0% |
| Regorafenib | 98.1% | 98.3% | -0.1% |
| Encorafenib | 97.5% | 98.0% | -0.6% |
| Vemurafenib | 97.4% | 92.8% | +4.6% |
| Ponatinib | 97.3% | 99.4% | -2.1% |
| Dabrafenib | 96.8% | 98.3% | -1.6% |
| Nilotinib | 95.5% | 85.8% | +9.7% |
| Dasatinib | 93.7% | 80.6% | +13.1% |
| Sorafenib | 90.9% | 98.5% | -7.6% |
| Pacritinib | 78.5% | 58.5% | +20.0% |
| Erdafitinib | 77.3% | 54.1% | +23.3% |
| Apatinib | 52.2% | 94.1% | -41.9% |
| Pazopanib | 50.5% | 79.3% | -28.8% |
| Tivozanib | 49.3% | 41.8% | +7.5% |
| Gedatolisib | 48.5% | 56.5% | -8.1% |
| Rabusertib | 42.8% | 41.1% | +1.7% |
| Crizotinib | 41.4% | — | — |
| Dacomitinib | 40.0% | 46.6% | -6.7% |
| Umbralisib | 26.8% | 65.3% | -38.5% |
| Axitinib | 24.9% | — | — |
| Bosutinib | 22.8% | — | — |
| Imatinib | 19.2% | — | — |
| Gefitinib | 19.2% | — | — |
| Tenalisib | 19.2% | — | — |
| Osimertinib | 18.7% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| Breast Cancer | Breast | ref |
| carcinoma_breast | Breast | ref |
| carcinoma_lung | Lung | ref |
| lymphoid_neoplasm_haematopoietic_and_lymphoid_tissue | Blood/Lymphatic System | ref |
| carcinoma_biliary_tract | Biliary Tract | ref |
| carcinoma_large_intestine | Large Intestine | ref |
| carcinoma_ovary | Ovary | ref |
| BTCA-SG | Biliary Tract | ref |
| LUAD-US | Lung | ref |
| LUSC-US | Lung | ref |
| LUAD | Lung | ref |
| LUSC | Lung | ref |
| BRCA | Breast | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 22.7ms